Modified esterase

By engineering the protein of Arthrobacter esterase, a modified esterase was developed, which solved the problems of low hydrolysis efficiency and poor stereoselectivity of (1R,3R)-chlorocypermethrin methyl ester in the existing technology, and achieved efficient production of high-purity λ-trifluorocypermethrin.

CN119013406APending Publication Date: 2024-11-22AMANO ENZYME INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202380032102.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-05
Filing Date
2023-04-05
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing technologies are difficult to efficiently and stereoselectively hydrolyze the ester compounds (methyl chlorofluorocypermethrin) of the (1R,3R) form of λ-trifluorocypermethrin, resulting in low yield, high cost, and issues related to wastewater discharge regulations.

Method used

By protein engineering esterases derived from Arthroblastus, specific amino acid sites were mutated to enhance their reactivity to (1R,3R)-chlorofluorocypermethrin, thus developing modified esterases.

Benefits of technology

The efficient hydrolysis of (1R,3R)-chlorofluorocypermethrin methyl ester was achieved to generate high-purity λ-trifluorocypermethrin, which improved reactivity and stereoselectivity and reduced costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005068069210000071
    Figure BDA0005068069210000071
  • Figure BDA0005068069210000081
    Figure BDA0005068069210000081
  • Figure BDA0005068069210000082
    Figure BDA0005068069210000082
Patent Text Reader

Abstract

The present invention provides a modified esterase of any one of the following (i) to (iii): (i) a modified esterase containing an amino acid sequence in which at least one amino acid selected from the group consisting of the following (1) to (24) in the amino acid sequence represented by SEQ ID NO: 1 or 3 is substituted with another amino acid: (1) V64 (2) S65 (3) A102 (4) A109 (5) L151 (6) I153 (7) Y173 (8) Y197 (9) L200 (10) I211 (11) F217 (12) S220 (13) D222 (14) D227 (15) L229 (16) L242 (17) A245 (18) V257 (19) L298 (20) T301 (21) V326 (22) (ii) a modified esterase in which one or more amino acids are further substituted (however, excluding the amino acid site substituted in (i)), added, inserted or deleted (however, excluding the amino acid site substituted in (i)) in the modified esterase of (i), and converted to (1R, 3R)-methyl3-(2-chloro-3, 3, 3-trifluoro-1-propylene-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4- the reactivity of the 1, 2-dimethylcyclopropane-1-carboxylic acid ester is further improved compared to the reactivity of an esterase comprising the amino acid sequence of SEQ ID NO: 1 or 3; (iii) a modified esterase in which the amino acid other than the amino acid substituted in (i) is further substituted with another amino acid among the modified esterase in (i), the modified esterase having 70% or more identity with the modified esterase in (i) and being p-(1R, 3R)-methyl3-(2-chloro-3, 3, 3-trifluoro-1-propylene-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl)-2, 3, 4-triazole-1-yl The reactivity of the 1, 2-dimethylcyclopropane-1-carboxylic acid ester is further improved compared to the reactivity of an esterase comprising the amino acid sequence of SEQ ID NO: 1 or 3.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a novel modified esterase, and more particularly to a modified esterase having enhanced reactivity to a specific substrate. Background Art

[0002] Cyhalothrin acid (hereinafter referred to as "CA") is used as a raw material for the synthesis of cyhalothrin, a pyrethroid insecticide. There are four isomers of CA ((1R,3R)-CA, (1R,3S)-CA, (1S,3R)-CA, (1S,3S)-CA), and cyhalothrin synthesized from (1R,3R)-CA (also called "λ-cyhalothrin acid") has the highest insecticidal effect. CA is industrially produced as a mixture of two isomers of CA ((1R,3R)-CA and (1S,3S)-CA) using a chemical synthesis method.

[0003] For example, Patent Document 1 discloses that an esterase derived from Arthrobacter globiformis decomposes 1R, 3R ((+)-trans) specific chrysanthemic acid ethyl ester. Patent Document 2 discloses an example of modifying an esterase derived from Arthrobacter globiformis to an enzyme that decomposes 1R, 3S ((+)-cis) specific chrysanthemic acid ethyl ester. In addition, Non-Patent Document 1 discloses that an esterase derived from Arthrobacter globiformis or an esterase from another source decomposes 1R, 3R ((+)-trans) specific or 1S, 3R ((-)-trans) specific chrysanthemic acid ethyl ester. Prior art literature Patent Literature

[0004] Patent Document 1: Japanese Patent Application Laid-Open No. 5-56787 Patent Document 2: International Publication No. 2020 / 116331 Non-patent literature

[0005] Non-patent document 1: Satoshi Mitsuda et al., Agric. Biol. Chem., 55(11), 2865-2870, 1991. Summary of the invention Problem that the invention aims to solve

[0006] γ-cyhalothrin is the optically active form with the highest insecticidal effect among the stereoisomers of cyhalothrin. Therefore, it is expected to selectively produce λ-trifluorochloric acid, which is a partial skeleton thereof. As a common method for producing λ-trifluorochloric acid, for example, stereoselective hydrolysis using a chemical catalyst and purification using a chiral chromatographic column can be cited. However, this method has problems in terms of yield, cost or wastewater discharge regulations. Therefore, it is expected to establish a production method using an enzyme that can solve these problems. However, there is no report of an enzyme that efficiently and stereoselectively hydrolyzes only the (1R, 3R) form of the ester compound of λ-trifluorochloric acid (methyl cyhalothrate (hereinafter referred to as "MC")). Therefore, an object of the present invention is to provide a novel esterase useful for the production of (1R,3R)-CA (λ-trifluorochloracetic acid). Means to solve the problem

[0007] The present inventors focused on the 5-fold mutant modified esterase derived from Arthrobacter sphaeroides reported in Patent Document 2. The esterase has high reactivity to (1R, 3S)-chrysanthemic acid ethyl ester and low reactivity to (1R, 3R)-MC. Therefore, the present inventors attempted to use protein engineering methods to improve the reactivity of the esterase to (1R, 3R)-MC. After repeated experiments, the present inventors successfully identified multiple candidate mutation sites in the 5-fold mutant modified esterase that effectively improve the reactivity to (1R, 3R)-MC, and completed the present invention by further advancing research based on the relevant findings. That is, the present invention is as follows. [1] A modified esterase, which is any one of the following modified esterases (i) to (iii): (i) a modified esterase comprising an amino acid sequence in which at least one amino acid at a position selected from the group consisting of the following (1) to (24) in the amino acid sequence of SEQ ID NO: 1 or 3 is substituted with another amino acid; (1) V64 (2)S65 (3)A102 (4)A109 (5)L151 (6)I153 (7)Y173 (8)Y197 (9)L200 (10)I211 (11)F217 (12)S220 (13)D222 (14)D227 (15)L229 (16)L242 (17)A245 (18)V257 (19)L298 (20)T301 (21)V326 (22)S329 (23) A350 (24)T371 (ii) a modified esterase, wherein in the modified esterase of (i), one or more amino acids are further substituted (however, excluding the amino acid sites substituted in (i)), added, inserted or deleted (however, excluding the amino acid sites substituted in (i)), and the reactivity to (1R,3R)-methyl 3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylate is further improved compared to the reactivity of the esterase consisting of the amino acid sequence of SEQ ID NO: 1 or 3; (iii) A modified esterase, wherein in the modified esterase of (i), an amino acid other than the amino acid substituted in (i) is further substituted with another amino acid, wherein the modified esterase has an identity of more than 70% with the modified esterase of (i) and has a reactivity to (1R,3R)-methyl 3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylate that is further improved compared to the reactivity of the esterase consisting of the amino acid sequence of sequence number 1 or 3. [2] The modified esterase according to [1], wherein in (i), the amino acid substitution is at least one selected from the group consisting of: (1)V64M (2)S65A (3)A102S (4)A109T (5) L151F, L151M or L151W (6)I153V (7)Y173F (8)Y197F (9) L200F (10)I211V or I211M (11)F217K (12)S220W (13)D222G (14) D227C or D227E (15)L229G (16) L242C, L242I, L242M or L242W (17)A245T (18)V257I (19)L298H (20)T301A (21)V326I (22) S329D, S329G or S329N (23) A350D (24)T371A. [3] A nucleic acid encoding the modified esterase described in [1] or [2]. [4] An expression cassette or recombinant vector comprising the nucleic acid described in [3]. [5] A transformant obtained by transformation using the expression cassette or recombinant vector described in [4]. [6] A method for producing a modified esterase, comprising the step of culturing the transformant described in [5]. [7] An enzyme agent comprising the modified esterase described in [1] or [2]. [8] The enzyme agent according to [7], which is used for producing (1R,3R)-3-((1Z)-2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylic acid. [9] A method for producing (1R,3R)-3-((1Z)-2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylic acid, comprising the step of allowing the modified esterase described in [1] or [2] to act on (1R,3R)-methyl 3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylate. Effects of the Invention

[0009] The modified esterase of the present invention can act on (1R, 3R)-MC with high reactivity, and as a result, (1R, 3R)-CA can be efficiently produced. DETAILED DESCRIPTION

[0010] Some of the terms used in the description of the present invention are explained below.

[0011] <Amino Acids> In this specification, according to convention, there are cases where amino acids are represented by one letter. The details are as follows: Glycine: G Alanine: A Valine: V Leucine: L Isoleucine: I Phenylalanine: F Tyrosine: Y Tryptophan: W Serine: S Threonine: T Cysteine: C Methionine: M Aspartic acid: D Glutamate: E Asparagine: N Glutamine: Q Lysine: K Arginine: R Histidine: H Proline: P

[0012] <Amino acid sequence> In the present specification, the left end of the amino acid sequence is the N-terminus, and the right end is the C-terminus.

[0013] <Amino Acid Types> In this specification, "non-polar amino acids" include alanine, valine, leucine, isoleucine, proline, methionine, phenylalanine and tryptophan. "Uncharged amino acids" include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. "Acidic amino acids" include aspartic acid and glutamic acid. "Basic amino acids" include lysine, arginine and histidine.

[0014] <Replacement> In this specification, "replacement" refers not only to the situation of artificially introducing the replacement of amino acid residues, but also includes the situation of naturally introducing the replacement of amino acid residues, that is, it also includes the situation that the original amino acid residues are different. In this specification, the replacement of amino acid residues can be artificial replacement or natural replacement, preferably artificial replacement.

[0015] In this specification, the mutation caused by amino acid substitution is represented by a combination of one letter representing the amino acid residue before substitution, a number representing the amino acid residue position where amino acid substitution occurs, and one letter representing the amino acid residue after substitution. For example, when the 328th alanine is replaced with glycine, it is represented as "A328G". In addition, when representing the combination (combination) of two mutations, the symbol " / " is used. For example, if the 328th alanine is replaced with a mutation of glycine and the 221st alanine is replaced with a mutation of phenylalanine, it is represented as "A328G / A221F".

[0016] <Modified esterase> In the present specification, "modified esterase" is an esterase obtained by modifying an esterase as a benchmark (hereinafter referred to as "benchmark esterase"). In the present specification, the benchmark esterase is typically an esterase having an amino acid sequence of sequence number 1 or an esterase having an amino acid sequence of sequence number 3. In addition, the esterase having an amino acid sequence of sequence number 3 is a wild-type esterase derived from Arthrobacter sphericalus. In addition, the esterase having an amino acid sequence of sequence number 1 is a 5-fold mutant esterase in which 5 amino acids (A221F / N222D / F298L / D326V / A328G) are replaced in the wild-type esterase derived from Arthrobacter sphericalus.

[0017] <Methyl cyhalothrin> In the present specification, methyl cyhalothricin (sometimes referred to as "MC") refers to a substance represented by the substance name methyl 3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylate (the following structural formula), and unless otherwise specified, refers to a racemic form of the (1R,3R)-isomer and the (1S,3S)-isomer.

[0018] [Chemistry 1]

[0019] In addition, trifluorochloroacetic acid (sometimes referred to as "CA") is a substance represented by the substance name 3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylic acid (hereinafter [Chemical 2]), and unless otherwise specified, refers to a mixture of four isomers, namely, (1R,3R)-isomer, (1R,3S)-isomer, (1S,3R)-isomer, and (1S,3S)-isomer.

[0020] [Chemistry 2]

[0021] Furthermore, λ-trifluorochloroacetic acid (sometimes referred to as "λ-CA" or "(1R,3R)-CA") refers to a substance represented by the substance name (1R,3R)-3-((1Z)-2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylic acid (hereinafter [Chemical 3]).

[0022] [Chemistry 3]

[0023] <Nucleic Acids> In this specification, "nucleic acid" includes both deoxyribonucleic acid and ribonucleic acid. In one embodiment, the "nucleic acid" can be deoxyribonucleic acid. In addition, in another embodiment, the "nucleic acid" can be ribonucleic acid. In addition, in another embodiment, the "nucleic acid" can be a chimera of deoxyribonucleic acid and ribonucleic acid.

[0024] 1. Modified esterase The modified esterase of the present invention is a novel esterase that specifically acts on a substrate having a specific structure (e.g., a compound composed of a dimethylcyclopropane skeleton and a carboxylic acid ester, preferably a compound composed of a dimethylcyclopropane skeleton, 1-propylene and a carboxylic acid ester, and particularly preferably (1R, 3R)-MC), and as a result, can efficiently synthesize λ-trifluorochloracetic acid (i.e., (1R, 3R)-CA). In addition, the substrate is described in more detail in "7. Method for producing (1R, 3R)-CA".

[0025] The modified esterase of the present invention is a substance obtained by substituting a specific amino acid in a standard esterase, and specifically contains an amino acid sequence represented by (i) to (iii) below or a sequence consisting of the amino acid sequence:

[0026] (i) a modified esterase comprising an amino acid sequence in which at least one amino acid at a position selected from the group consisting of the following (1) to (24) is substituted with another amino acid in the amino acid sequence of SEQ ID NO: 1 or 3; (1) V64 (2)S65 (3)A102 (4)A109 (5)L151 (6)I153 (7)Y173 (8)Y197 (9)L200 (10)I211 (11)F217 (12)S220 (13)D222 (14)D227 (15)L229 (16)L242 (17)A245 (18)V257 (19)L298 (20)T301 (21)V326 (22)S329 (23) A350 (24)T371

[0027] (ii) In the modified esterase of (i), one or more amino acids are further substituted (but excluding the amino acid site substituted in (i)), added, inserted or deleted (but excluding the amino acid site substituted in (i)), and the reactivity to (1R,3R)-methyl 3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylate is further improved compared to the reactivity of the esterase consisting of the amino acid sequence of SEQ ID NO: 1 or 3;

[0028] (iii) A modified esterase in which an amino acid other than the amino acid substituted in (i) is further replaced by another amino acid, wherein the modified esterase has an identity of more than 70% with the modified esterase in (i) and has a reactivity to (1R,3R)-methyl 3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylate that is further improved compared to the reactivity of the esterase composed of the amino acid sequence of sequence number 1 or 3.

[0029] First, the modified esterase (i) will be described. The modified esterase of (i) comprises an amino acid sequence in which at least one original amino acid of the above-mentioned (1) to (24) in the reference esterase is replaced by another amino acid. In the esterase of the present invention, the number of substituted amino acids may generally be 1 or more, preferably 2 or more, and more preferably 3 or more (e.g. 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 or more).

[0030] Regarding the replacement of the original amino acid with another amino acid, the type of the replaced amino acid is not particularly limited as long as it can exert the desired effect of the present invention, but there is a case where conservative substitution is preferred. Conservative substitution of amino acids is a well-known technique for those skilled in the art. As an example, the type of amino acid after replacement can be selected with reference to the above-mentioned <Type of amino acid>, but it is not limited thereto.

[0031] In one embodiment, the number of substituted amino acids is 1, and the substitution sites may be the following sites. (5)L151 (9)L200 (12)S220 (14)D227 (15)L229 (16)L242 (17)A245 (22)S329

[0032] In another embodiment, the number of substituted amino acids is 2, and the substitution sites may be the following sites. (5) L151 and (9) L200 (5) L151 and (10) I211 (5) L151 and (13) D222 (5) L151 and (15) L229 (5) L151 and (16) L242 (5) L151 and (22) S329

[0033] In another embodiment, the number of substituted amino acids is 3, and the substitution sites may be the following sites. (5) L151, (16) L242 and (3) A102 (5) L151, (16) L242 and (4) A109 (5) L151, (16) L242 and (6) I153 (5) L151, (16) L242 and (7) Y173 (5) L151, (16) L242 and (8) Y197 (5) L151, (16) L242 and (9) L200 (5) L151, (16) L242 and (11) F217 (5) L151, (16) L242 and (13) D222 (5) L151, (16) L242 and (14) D227 (5) L151, (16) L242 and (-) L231 (5) L151, (16) L242 and (18) V257 (5) L151, (16) L242 and (19) L298 (5) L151, (16) L242 and (21) V326 (5) L151, (16) L242 and (22) S329 (5) L151, (16) L242 and (23) A350 (5) L151, (16) L242 and (24) T371

[0034] In another embodiment, the number of substituted amino acids is 4, and the substitution sites may be the following sites. (5) L151, (16) L242, (10) I211 and (20) T301 (5) L151, (16) L242, (1) V64 and (2) S65

[0035] In another embodiment, the number of substituted amino acids is 1 to 4, and the substitution sites may be 1 to 4 selected from the group consisting of the following. (5) L151, (16) L242, (22) S329 and (9) L200

[0036] In addition, in a preferred embodiment, the amino acid after substitution at each site may be the following sites. (1)V64M (2)S65A (3)A102S (4)A109T (5) L151F, L151M or L151W (6)I153V (7)Y173F (8)Y197F (9) L200F (10)I211V or I211M (11)F217K (12)S220W (13)D222G (14) D227C or D227E (15)L229G (16) L242C, L242I, L242M or L242W (17)A245T (18)V257I (19)L298H (20)T301A (21)V326I (22) S329D, S329G or S329N (23) A350D (24)T371A

[0037] In one embodiment, the number of amino acids to be substituted is 1 to 4, and the substitution may be 1 to 4 selected from the group consisting of the following. (5) L151F, (16) L242M, (22) S329N and (9) L200F

[0038] In a preferred embodiment, the modified esterase of the present invention comprises an amino acid sequence having the following amino acid substitutions in SEQ ID NO: 1 or 3 or consists of the amino acid sequence.

[0039] <Modified esterase having one amino acid substitution in the reference esterase> (E-1)L151F (E-2)L151M (E-3)L151W (E-4)S220W (E-5)D227C (E-6)L229G (E-7)A245T (E-43)L200F (E-44)L242M (E-45)S329N

[0040] <Modified esterase having two amino acid substitutions in the reference esterase> (E-8)L151F / I211V (E-9)L151F / I211M (E-10)L151F / D222G (E-11)L151F / L229V (E-12)L151F / L242C (E-13)L151F / L242I (E-14)L151F / L242M (E-15)L151F / L242W (E-16)L151F / S329D (E-17)L151F / S329N (E-46)L151F / L200F

[0041] <Modified esterase with three amino acid substitutions in the reference esterase> (E-18)L151F / L242M / A102S (E-19)L151F / L242M / A109T (E-20)L151F / L242M / I153V (E-21)L151F / L242M / Y173F (E-22)L151F / L242M / Y197F (E-23)L151F / L242M / L200F (E-24)L151F / L242M / F217K (E-25)L151F / L242M / D222G (E-26)L151F / L242M / D227E (E-27)L151F / L242M / L231M (E-28)L151F / L242M / V257I (E-29)L151F / L242M / L298H (E-30)L151F / L242M / V326I (E-31)L151F / L242M / S329G (E-32)L151F / L242M / S329D (E-33)L151F / L242M / S329N (E-34)L151F / L242M / A350D (E-35)L151F / L242M / T371A

[0042] <Modified esterase with four amino acid substitutions in the reference esterase> (E-36)L151F / L242M / I211V / T301A (E-37)L151F / L242M / V64M / S65A

[0043] In one embodiment, the modified esterase of the present invention may be a fusion product of an esterase portion and other polypeptides or proteins. In the modified esterase of the present invention, the fused polypeptide or protein is not particularly limited, but examples thereof include sequences that play a role in purification, such as multiple amino acid residues, and polypeptides that can improve the stability of the esterase during recombinant production.

[0044] Next, the modified esterase (ii) will be described. The modified esterase of (ii) is an esterase obtained by further introducing amino acid modifications to the modified esterase of (i) above. However, the additionally introduced modification site is introduced into a site other than a specific amino acid substitution site in the modified esterase of (i). The additionally introduced amino acid modification can be any one (e.g., only substitution) or two or more (e.g., substitution and insertion) of amino acid substitution, addition, insertion, and deletion. In the modified esterase of (ii), as long as the desired effect of the present invention can be exerted, the number of additionally introduced amino acid modifications is not particularly limited, but is usually 1 or more, for example, 1 to 80, preferably 1 to 70, 1 to 60, 1 to 50, 1 to 40 or 1 to 30, more preferably 1 to 20, 1 to 10, 1 to 8, 1 to 7, 1 to 6, 1 to 5 or 1 to 4, further preferably 1 to 3, and particularly preferably 1 or 2.

[0045] In addition, although not wishing to be bound by theory, positions 59 (serine residue), 62 (lysine residue) and 148 (tyrosine residue) of the esterase of SEQ ID NO: 1 or 3 are considered to be active catalyst residues. Therefore, there may be cases where it is preferred not to substitute or delete these sites.

[0046] In addition, the modified esterase of (ii) is characterized in that, while having the above-mentioned amino acid sequence, the reactivity to (1R,3R)-MC is further improved compared to the reactivity of the reference esterase (i.e., the esterase composed of the amino acid sequence of sequence number 1 or 3). More specifically, in the reaction of generating (1R,3R)-CA using (1R,3R)-MC as a substrate, the modified esterase of (ii) has an esterase activity of 1.03 times or more, preferably 1.05 times or more, 1.1 times or more, 1.2 times or more, more preferably 1.5 times or more, and further preferably 2 times or more relative to the reference esterase (esterase having the amino acid sequence of sequence number 1 or 3). Alternatively, in the reaction of generating (1R,3R)-CA using (1R,3R)-MC as a substrate, the modified esterase of (ii) has an activity equivalent to the activity of the modified esterase of (i).

[0047] Next, the modified esterase (iii) will be described. The modified esterase (iii) is an esterase obtained by further introducing an amino acid substitution into the modified esterase (i) above. However, the site of the additionally introduced amino acid substitution is introduced into a site other than the specific amino acid substitution site in the modified esterase (i).

[0048] The sequence identity between the modified esterase of (iii) and the modified esterase of (i) is not particularly limited as long as the desired effect can be exerted, but is usually 70% or more, preferably 75% or more, 80% or more, or 85% or more, more preferably 90% or more, 95% or more, 96% or more, 97% or more, or 98% or more, and particularly preferably 99% or more.

[0049] In addition, sequence identity can be determined by a known method. For example, it can be obtained by bl2seq program (Tatiana A. Tatsusova, Thomas L. Madden, FEMS Microbiol. Lett., Vol. 174, p247-250, 1999) of BLASTPACKAGE [sgi 32 bit edition, Version 2.0.12; available from National Center for Biotechnology Information (NCBI)]. When this method is used, the parameters can be set to Gap insertion Cost value: 11 and Gap extension Cost value: 1.

[0050] The modified esterase (iii) is also characterized in that the reactivity to (1R, 3R)-MC is further improved compared to the reactivity of the benchmark esterase, similar to the modified esterase (ii). That is, in the reaction of generating (1R, 3R)-CA using (1R, 3R)-MC as a substrate, the modified esterase (iii) has an esterase activity of 1.03 times or more, preferably 1.05 times or more, 1.1 times or more, 1.2 times or more, more preferably 1.5 times or more, and even more preferably 2 times or more relative to the benchmark esterase. Alternatively, in the reaction of generating (1R, 3R)-CA using (1R, 3R)-MC as a substrate, the modified esterase (iii) has an activity equivalent to that of the modified esterase (i).

[0051] 2. Nucleic acid encoding modified esterase The present invention also provides a nucleic acid encoding the modified esterase of the present invention (hereinafter sometimes referred to as "nucleic acid of the present invention").

[0052] The nucleic acid of the present invention is a nucleic acid encoding the modified esterase of the present invention. The nucleic acid of the present invention is not particularly limited as long as it is a nucleic acid encoding the modified esterase of (i) to (iii) described above.

[0053] The nucleic acid of the present invention can be prepared by a method known per se. As an example, the base sequence shown in sequence number 13 is a base sequence encoding a benchmark esterase consisting of the amino acid sequence shown in sequence number 1, and the base sequence shown in sequence number 15 is a base sequence encoding a benchmark esterase consisting of the amino acid sequence shown in sequence number 3. Therefore, the nucleic acid of the present invention can be appropriately designed using sequence number 13 or 15 as a benchmark sequence by a method known per se. In addition, codon degeneracy can be considered according to the host expressing the nucleic acid of the present invention.

[0054] In one embodiment, an example of the nucleic acid of the present invention is shown in SEQ ID NOs: 17 to 24. In addition, these are nucleic acid sequences encoding modified esterases prepared based on the reference esterase of SEQ ID NO: 1. SEQ ID NO: 17: L151F mutant SEQ ID NO: 18: L242M mutant SEQ ID NO: 19: S329N mutant SEQ ID NO. 20: L200F mutant SEQ ID NO: 21: L151F / L242M mutant SEQ ID NO: 22: L151F / L242M / S329N mutant SEQ ID NO: 23: L151F / L242M / L200F mutant SEQ ID NO: 24: L151F / L242M / L200F / S329N mutant

[0055] In addition, the nucleic acid of the present invention is not limited to the nucleic acid sequence encoding the modified esterase of the present invention itself, but also includes nucleic acid sequences having an identity of 75% or more, preferably 80% or more, 85% or more, 90% or more, more preferably 95% or more, 96%, 97% or more, 98% or more, and particularly preferably 99% or more to the nucleic acid sequence. As long as it encodes a polypeptide having an esterase activity equivalent to that of the modified esterase of the present invention, it is included in the nucleic acid of the present invention.

[0056] At this time, the "homology" of the nucleic acid sequence is calculated using a public or commercially available software that is equipped with an algorithm for comparing the reference sequence as the query sequence. Specifically, BLAST, FASTA or GENETYX (manufactured by Software Development Co., Ltd.) can be used. When determining the homology of sequences using these, the homology score can be determined using the default parameters, or the homology score can be determined using appropriately changed parameters.

[0057] In addition, the same applies to nucleic acids composed of nucleic acid sequences complementary to the nucleic acid of the present invention and nucleic acids that hybridize under stringent conditions, as long as they encode a polypeptide having an activity equivalent to the esterase activity possessed by the modified esterase of the present invention, they are included in the nucleic acid of the present invention. In this case, "stringent conditions" refers to conditions of incubating at 50°C to 65°C for 4 hours to overnight in 6×SSC (1×SSC, 0.15M NaCl, 0.015M sodium citrate, pH 7.0) containing 0.5% SDS, 5×Denhartz〔Denhartz's, 0.1% bovine serum albumin (BSA), 0.1% polyvinyl pyrrolidone, 0.1% Ficoll 400〕and 100μg / ml salmon sperm DNA. Hybridization under stringent conditions can be specifically performed by the following method. That is, a nylon membrane on which a DNA library or cDNA library is immobilized is prepared, and the nylon membrane is blocked at 65°C in a prehybridization solution containing 6×SSC, 0.5% SDS, 5×Denhartz, and 100μg / ml salmon sperm DNA. Then, each probe labeled at 32P is added and incubated at 65°C overnight. The nylon membrane is washed in 6×SSC at room temperature for 10 minutes; in 2×SSC containing 0.1% SDS at room temperature for 10 minutes; and in 0.2×SSC containing 0.1% SDS at 45°C for 30 minutes, and then the DNA specifically hybridized with the probe can be detected by radioautography.

[0058] In one embodiment, as described above, the modified esterase of the present invention may be a substance formed by fusion of an esterase part with other polypeptides or proteins. Therefore, the nucleic acid of the present invention may be a base sequence encoding an esterase part and other polypeptides or proteins.

[0059] The method for expressing the nucleic acid of the present invention in a host is not particularly limited, and a known method per se can be used.

[0060] 3. Expression cassette or recombinant vector The present invention also provides an expression cassette or recombinant vector containing the nucleic acid of the present invention (hereinafter referred to as "the expression cassette of the present invention", "the recombinant vector of the present invention", or "the expression cassette or recombinant vector of the present invention").

[0061] The expression cassette or recombinant vector of the present invention can be prepared by linking a promoter and a terminator to the nucleic acid of the present invention, or by inserting the expression cassette of the present invention or the nucleic acid of the present invention into an expression vector.

[0062] In the expression cassette of the present invention or the recombinant vector of the present invention, as a control factor, in addition to a promoter and a terminator, transcription factors such as an enhancer, a CCAAT box, a TATA box, and an SPI site may also be contained as needed. These control factors only need to be connected to the nucleic acid of the present invention in a manner that can act. The connection that can act means that various control factors that regulate the nucleic acid of the present invention and the nucleic acid of the present invention are connected in a state that can act in the host cell.

[0063] In the recombinant vector of the present invention, the vector is preferably an expression vector. As an expression vector, a vector constructed for gene recombination from a phage, plasmid or virus that can autonomously proliferate in a host can be preferably used. Such expression vectors are well known, and for example, commercially available expression vectors include: pQE vectors (QIAGEN Co., Ltd.), pDR540, pRIT2T (GE Healthcare Bioscience Co., Ltd.), pET vectors (Merck Co., Ltd.), etc. For expression vectors, it is sufficient to select a suitable combination with a host cell for use. For example, when Escherichia coli is used as a host cell, a combination of a pQE vector and a DH5α Escherichia coli strain, a combination of a pET vector and a BL21 (DE3) Escherichia coli strain, or a combination of a pDR540 vector and a JM109 Escherichia coli strain, etc. can be cited.

[0064] 4. Transformants The present invention also provides a transformant transformed using the expression cassette or recombinant vector of the present invention (hereinafter sometimes referred to as "the transformant of the present invention").

[0065] The host used for producing the transformant of the present invention is not particularly limited as long as it has the following characteristics (1) to (4): (1) can be introduced into expression cassettes or recombinant vectors, (2) The expression cassette or recombinant vector is stable, (3) It can proliferate autonomously and (4) The ability to express the gene in the introduced expression cassette or recombinant vector. Examples of such hosts include bacteria belonging to the genus Escherichia such as Escherichia coli, the genus Bacillus such as Bacillus subtilis, the genus Pseudomonas such as Pseudomonas putida, filamentous fungi, yeast, etc. In addition, animal cells, insect cells, plants, etc. may be used.

[0066] The transformant of the present invention can be prepared by introducing the nucleic acid of the present invention, the expression cassette of the present invention or the recombinant vector of the present invention into the host. As long as the target gene can be expressed, there is no particular limitation on the site where the nucleic acid of the present invention is introduced, and it can be on a plasmid or on a genome. As a specific method for introducing the expression cassette of the present invention or the recombinant vector of the present invention, for example, a recombinant vector method and a genome editing method can be cited. The conditions for introducing the expression cassette or the recombinant vector into the host can be appropriately set according to the type of the host. When the host is a bacterium, for example, a method using competent cells treated with calcium ions and an electrofection method can be cited. When the host is yeast, for example, electroporation (electroporation), spheroplast method and lithium acetate method can be cited. When the host is an animal cell, for example, electrofection, calcium phosphate method and lipofection method can be cited. When the host is an insect cell, for example, calcium phosphate method, lipofection method and electrofection method can be cited. When the host is a plant cell, for example, electrofection, Agrobacterium method, gene gun method and PEG method can be cited.

[0067] Whether the expression cassette of the present invention or the recombinant vector of the present invention has been introduced into the host can be confirmed by a known method such as PCR, Southern hybridization or Northern hybridization.

[0068] When confirming whether the expression cassette of the present invention or the recombinant vector of the present invention has been introduced into the host by the PCR method, for example, genomic DNA or the expression cassette or the recombinant vector can be separated / purified from the transformant. For the separation / purification of the expression cassette or the recombinant vector, for example, when the host is a bacterium, it is carried out based on the lysate obtained by dissolving the bacteria. As a method of lysing bacteria, for example, lysozymes such as lysozyme can be used for treatment, and proteases and other enzymes and surfactants such as sodium lauryl sulfate (SDS) can be used in combination as needed.

[0069] Furthermore, physical disruption methods such as freeze-thaw and French press treatment may be combined. For the separation / purification of nucleic acids from lysates, for example, protein removal treatment using phenol treatment and protease treatment, ribonuclease treatment, alcohol precipitation treatment, and commercially available kits may be appropriately combined.

[0070] The cleavage of the nucleic acid can be carried out according to conventional methods (e.g., restriction enzyme treatment). As the restriction enzyme, for example, a type II restriction enzyme that acts on a specific nucleotide sequence is used. The nucleic acid is bound to the expression cassette or expression vector using, for example, DNA ligase.

[0071] Afterwards, the DNA isolated / purified is used as a template, and the DNA-specific primers of the present invention are designed to perform PCR. The amplified product obtained by PCR is subjected to agarose gel electrophoresis, polyacrylamide gel electrophoresis, capillary electrophoresis, etc., and stained with ethidium bromide and SYBR Green solution, and then detected as a band using the amplified product, thereby confirming that it has been transformed.

[0072] In addition, the amplification product can also be detected by performing PCR using primers previously labeled with fluorescent dyes, etc. Furthermore, a method can also be adopted in which the amplification product is fixed to a microplate, etc., and the amplification product is confirmed by fluorescence and enzyme reaction, etc.

[0073] 5. Method for producing modified esterase The present invention also provides a method for producing a modified esterase comprising the step of culturing the transformant of the present invention (hereinafter sometimes referred to as "the production method of the present invention").

[0074] The culture conditions used in the production method of the present invention may be appropriately set in consideration of the nutritional and physiological properties of the transformant to be used.

[0075] The culture of the transformant can use a solid culture medium or a liquid culture medium, and can be preferably a liquid culture medium. In addition, when industrial production is carried out, it is preferably a ventilation stirring culture. As the nutrient source of the culture medium, the substances required for the growth and development of the transformant can be appropriately used. As a carbon source, as long as it is an internalizable carbon compound, for example, glucose, sucrose, lactose, maltose, molasses, pyruvic acid, etc. can be mentioned. As a nitrogen source, as long as it is an internalizable nitrogen compound, for example, peptone, meat essence, yeast extract, casein hydrolyzate, soybean meal alkaline extract can be mentioned. In addition to carbon sources and nitrogen sources, for example, salts of phosphates, carbonates, sulfates, magnesium, calcium, potassium, iron, manganese and zinc, specific amino acids and specific vitamins and biotin, etc. can also be used as needed.

[0076] The culture temperature only needs to be appropriately set within the range in which the transformant of the present invention can grow and develop and the transformant produces the modified esterase. In one embodiment, the culture temperature is about 15 to 37° C., but is not limited to these. As the timing of terminating the culture, the timing of terminating the culture can be considered when the modified esterase reaches the maximum yield. The culture time can be, for example, about 12 to 48 hours, but is not limited to these.

[0077] The modified esterase expressed by the transformant is present inside the transformant or in the culture medium. The modified esterase can be recovered by a known method per se, but an example of the recovery method is briefly described below.

[0078] In one embodiment, when the expressed modified esterase is present inside the transformant, it is separated from the culture supernatant by a method known per se, such as centrifuging the transformant. The culture supernatant is removed and the separated transformant is recovered. The separated transformant is treated with a mechanical method such as ultrasound or French pressing or an enzymatic method such as lysozyme, and is solubilized as needed using an enzyme such as a protease or a surfactant such as sodium lauryl sulfate (SDS), thereby obtaining a water-soluble fraction containing the modified esterase.

[0079] In addition, in other embodiments, when the expressed modified esterase is present in the culture medium, it can be provided for purification as it is, or it can be provided for purification after the modified esterase in the water-soluble component is concentrated. Concentration can be performed, for example, by using a step-by-step precipitation method using reduced pressure concentration, membrane concentration, salting-out treatment, a hydrophilic organic solvent (e.g., methanol, ethanol, and acetone). In addition, the purification of the modified esterase can be performed, for example, by appropriately combining methods such as gel filtration, adsorption chromatography, ion exchange chromatography, affinity chromatography, etc. The modified esterase thus purified can be circulated to the market after being powdered by freeze drying, vacuum drying, spray drying, etc. as needed.

[0080] 6. Enzyme containing modified esterase The present invention also provides an enzyme agent comprising the modified esterase of the present invention (hereinafter sometimes referred to as "the enzyme agent of the present invention").

[0081] The amount of the modified esterase of the present invention contained in the enzyme agent of the present invention can generally be 0.001 to 100% by weight, preferably 0.01 to 100% by weight, 0.1 to 100% by weight or 1 to 100% by weight, more preferably 5 to 100% by weight, 10 to 100% by weight, 20 to 100% by weight, 30 to 100% by weight, 40 to 100% by weight or 50 to 100% by weight, but is not limited to these.

[0082] The enzyme agent of the present invention may contain only the modified esterase of the present invention, but may contain other components as long as the desired effect is exerted. Examples of other components include: other enzymes other than the modified esterase of the present invention, additives, and culture residues produced in the production method of the present invention.

[0083] As other enzymes, for example, amylase (α-amylase, β-amylase, glucoamylase), glucosidase (α-glucosidase, β-glucosidase), β-galactosidase (α-galactosidase, β-galactosidase), protease (acid protease, neutral protease, alkaline protease), peptidase (leucine peptidase, aminopeptidase), lipase, esterase, cellulase, phosphatase (acid phosphatase, alkaline phosphatase), nuclease, deaminase, oxidase, dehydrogenase, glutaminase, pectinase, catalase, glucanase, transglutaminase, protein deamidase, pullulanase, etc. These other enzymes may contain one alone or in combination of a plurality of.

[0084] As additives, there are mentioned: excipients, buffers, suspending agents, stabilizers, preservatives, preservatives, physiological saline, etc. As excipients, there are mentioned: starch, dextrin, maltose, trehalose, lactose, D-glucose, sorbitol, D-mannitol, white sugar, glycerol, etc. As buffers, there are mentioned: phosphates, citrates, acetates, etc. As stabilizers, there are mentioned: propylene glycol, ascorbic acid, etc. As preservatives, there are mentioned: phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methyl parahydroxybenzoate, etc. As preservatives, there are mentioned: ethanol, benzalkonium chloride, p-hydroxybenzoic acid, chlorobutanol, etc. These additives may be contained alone or in combination of multiple types.

[0085] Examples of the culture residues include components derived from the culture medium, impurity proteins, and bacterial components.

[0086] The form of the enzyme agent of the present invention is not particularly limited, and examples thereof include liquid, solid (powder, granules, etc.), etc. The shape of the enzyme agent may be formed by a method known per se.

[0087] The modified esterase of the present invention, which is an active ingredient of the enzyme agent of the present invention, has high enzyme activity in the process of converting (1R,3R)-MC into (1R,3R)-CA. Therefore, in one embodiment of the enzyme agent of the present invention, the enzyme agent of the present invention is an enzyme agent for producing (1R,3R)-CA.

[0088] By allowing the enzyme of the present invention to act on a composition containing a compound composed of a dimethylcyclopropane skeleton and a carboxylic acid ester (e.g., (1R, 3R)-MC) under appropriate conditions, a composition containing (1R, 3R)-CA can be efficiently produced. In addition, the substrate of the enzyme of the present invention is described in detail in the "Method for producing (1R, 3R)-CA" described later.

[0089] 7. Method for producing (1R,3R)-CA The present invention also provides a method for producing (1R,3R)-3-((1Z)-2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylic acid (hereinafter referred to as "the method for producing (1R,3R)-CA of the present invention"), which comprises the step of allowing the modified esterase of the present invention to act on (1R,3R)-MC.

[0090] In the method for producing (1R,3R)-CA of the present invention, the (1R,3R)-MC serving as the matrix may be a purified product or a composition containing other components (hereinafter referred to as "composition containing (1R,3R)-MC"). The composition containing (1R,3R)-MC may use high-purity (1R,3R)-MC (for example, purity of 98% or more), or may use a matrix in which (1R,3R)-MC and (1S,3S)-MC coexist (for example, mixed MC of (1R,3R):(1S,3S)=1:1).

[0091] The content of (1R,3R)-MC contained in the composition containing (1R,3R)-MC is not particularly limited, and for example, 20% or more can be cited. From the viewpoint of further improving the content of (1R,3R)-CA in the product, the content of (1R,3R)-MC in the matrix is ​​preferably 30% or more, more preferably 40% or more, and further preferably 45% or more. The upper limit of the content range is not particularly limited, but for example, 100% or less, preferably 90% or less, and more preferably 70% or less can be cited. There is no particular limitation on the origin of the composition containing (1R,3R)-MC, and for example, a chemically synthesized origin can be cited.

[0092] As long as (1R, 3R)-CA can be produced, the reaction time, reaction temperature, pH of the reaction solution, etc. when the modified esterase is allowed to act on the substrate (e.g., a composition containing (1R, 3R)-MC) are not particularly limited. The reaction time is, for example, 10 minutes to 96 hours, preferably 1 hour to 72 hours, and more preferably 12 hours to 48 hours. The reaction temperature can be, for example, 10 to 90°C, preferably 20 to 80°C, and more preferably 30 to 50°C. The pH of the reaction solution can be, for example, 3 to 12, preferably 6 to 11, and more preferably 8 to 11. These reaction conditions can be appropriately selected according to the raw materials used and the target product. In addition, the optimal reaction conditions can be determined by preliminary experiments.

[0093] By using the method for producing (1R, 3R)-CA of the present invention, a composition containing (1R, 3R)-CA can be produced very efficiently. One embodiment of the method for producing a composition containing (1R, 3R)-CA of the present invention includes the following steps (1) and (2). In addition, after step (2), a step of recovering (1R, 3R)-CA from the obtained composition containing (1R, 3R)-CA can be added. (1) Step of providing a composition containing (1R,3R)-MC (2) A step of treating the provided composition containing (1R,3R)-MC with the modified esterase of the present invention

[0094] The content of (1R,3R)-CA in the composition containing (1R,3R)-CA obtained using the method for producing (1R,3R)-CA of the present invention is not particularly limited, but is generally 1% by weight or more, preferably 2% by weight or more, 3% by weight or more, 4% by weight or more or 5% by weight or more, more preferably 10% by weight or more, 12% by weight or more or 14% by weight or more, and particularly preferably 16% by weight or more.

[0095] In addition, the composition containing (1R,3R)-CA is preferably used as an agricultural chemical intermediate.

[0096] Although not wishing to be bound by theory, the substrate of the modified esterase of the present invention may be a compound represented by the following formula I consisting of a dimethylcyclopropane skeleton and a carboxylic acid ester.

[0097] [Chemistry 4]

[0098] In formula I, the structures of X1 and R are not particularly limited and can be any structure. As an example of X1, there can be mentioned: halo (fluoro, chloro, bromo, iodo, astatinyl, etc.), alkyl (methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl, etc.) and aryl (phenyl, biphenyl and naphthyl, etc.), but are not limited to these. In addition, as an example of R, there can be mentioned: alkyl (methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl, etc.) and aryl (phenyl, biphenyl and naphthyl, etc.), but are not limited to these. In addition, the carbon chains of these substituents can be straight chains or branched chains, and can also have cyclic structures and unsaturated bonds in the middle or at the ends.

[0099] Furthermore, these substituents may be further substituted with at least one of the following arbitrary substituents. Examples include: (1) halo groups, (2) Hydroxyl, (3) Cyano, (4) Nitro, (5) Carboxyl, (6) Alkenyl (C 2-10 alkenyl; for example, vinyl, allyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, butadienyl, hexatrienyl and their isomers), (7) Alkynyl (C 2-10 alkynyl; for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl and their isomers), (8) haloalkyl (e.g. monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, chloromethyl, chloroethyl, dichloroethyl and isomers thereof), (9) cyclic alkyl groups (which may contain heteroatoms in the ring) (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl), (10) aryl (e.g. phenyl, naphthyl), (11) heteroaryl (e.g., pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl), tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl), thiadiazolyl (e.g., 1,2,3-thiadiazolyl), , 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl), benzofuranyl, benzothiophenyl, indolyl, isoindolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, pteridinyl, imidazoxazolyl, imidazothiazolyl, imidazoimidazolyl), (12) Alkoxy (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentyloxy, tert-pentyloxy, neopentyloxy, 2-pentyloxy, 3-pentyloxy, n-hexyloxy, 2-hexyloxy), (13) alkylthio (e.g., methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, n-pentylthio, isopentylthio, tert-pentylthio, neopentylthio, 2-pentylthio, 3-pentylthio, n-hexylthio, 2-hexylthio), (14) an alkoxy group (same meaning as in (12) above) substituted with an aryl group (same meaning as in (10) above), (15) an alkylthio group (same as in (13) above) substituted with an aryl group (same as in (10) above), (16) an alkoxy group (same as the meaning of the above (12)) substituted with a heteroaryl group (same as the meaning of the above (11)), (17) an alkylthio group (same as in the above (13)) substituted with a heteroaryl group (same as in the above (11)), (18) cyclic alkyl (which may contain a hetero atom in the ring) oxy (e.g., cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, tetrahydrofuranyloxy, tetrahydropyranyloxy, aziridinyloxy, azetidinyloxy, pyrrolidinyloxy, piperidinyloxy, morpholinyloxy), (19) aryloxy groups (for example, groups in which an aryl group (same meaning as in (10) above) is bonded to an oxygen atom), (20) heteroaryloxy (for example, a group in which a heteroaryl group (same as in (11) above) is bonded to an oxygen atom), (21) a haloalkoxy group (for example, a haloalkyl group (same as in (8) above) bonded to an oxygen atom), (22) haloalkylthio groups (e.g., groups in which a haloalkyl group (same meaning as in (8) above) is bonded to a sulfur atom), (23) alkoxy substituted with hydroxyl group (same meaning as in (12) above), (24) an alkoxy group (same meaning as in (12) above) substituted with an alkoxy group (same meaning as in (12) above), (25) Amino acid, (26) amino groups mono- or di-substituted by alkyl groups, Among them, the "alkyl group" includes C 1-6 Specific examples of the alkyl group include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl, 2-pentyl, 3-pentyl, n-hexyl, and 2-hexyl. (27) Carbamoyl, (28) Carbamoyl groups mono- or di-substituted by alkyl groups (the "alkyl" has the same meaning as in (26) above) (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl) (29) sulfamoyl, (30) sulfamoyl groups which are mono- or di-substituted by alkyl groups (the "alkyl" has the same meaning as in (26) above) (e.g., methylsulfamoyl, ethylsulfamoyl, dimethylsulfamoyl, diethylsulfamoyl, ethylmethylsulfamoyl), (31) an alkanoyl group (e.g., a carbonyl group in which a hydrogen atom or an alkyl group (the "alkyl group" has the same meaning as in (26) above) is bonded to a carbon atom), (32) an aromatic acyl group (e.g., an aromatic group (same as in (10) above) and a carbonyl group bonded to a carbon atom), (33) Alkylsulfonylamino (e.g., sulfonylamino substituted with an alkyl group (the "alkyl group" has the same meaning as in (26) above)) (34) arylsulfonylamino (e.g. sulfonylamino substituted with aryl (same meaning as in (10) above)), (35) heteroarylsulfonylamino (e.g., sulfonylamino substituted with heteroaryl (same meaning as in (11) above)), (36) acylamino (e.g., amino substituted with acyl), Here, "acyl" refers to a C 1-6 Alkyl or C 6-10 The acyl group of the aromatic group. 1-6 "Alkyl" refers to an alkyl group having 1 to 6 carbon atoms in the above-mentioned "alkyl"; "C 6-10 The "aryl group" is an aryl group having 1 to 6 carbon atoms in the above-mentioned "aryl group". Specific examples of the acyl group include acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, acryloyl, methacryloyl, crotonyl, isocrotonyl, benzoyl, naphthoyl, etc. (37) alkoxycarbonylamino (e.g., carbonylamino substituted with an alkoxy group (same as in (12) above)), (38) alkylsulfonyl (e.g., sulfonyl substituted with an alkyl group (the "alkyl group" has the same meaning as in (26) above)), (39) alkylsulfinyl (e.g., sulfinyl substituted with an alkyl group (the "alkyl" has the same meaning as in (26) above)), (40) Alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl), etc. When there are two or more substituents, they may be the same or different.

[0100] The modified esterase of the present invention can be applied not only to the production of the above-mentioned (1R, 3R)-CA, but also to the production of the compound of the following formula II by allowing the modified esterase of the present invention to act on the compound of formula I.

[0101] [Chemistry 5]

[0102] Based on this aspect, the present invention also provides a method for producing a compound of formula II, comprising allowing the modified esterase of the present invention to act on a compound of formula I (hereinafter sometimes referred to as "the method for producing the compound of the present invention").

[0103] In the method for producing the compound of the present invention, the conditions under which the modified esterase of the present invention acts on the compound of formula I are not particularly limited as long as the modified esterase of the present invention hydrolyzes the compound of formula I to produce the compound of formula II. The relevant conditions may be the same as or different from the reaction conditions under which the known esterase can hydrolyze the ester. As an example, the following conditions can be cited, but are not limited to these.

[0104] Reaction time: usually 10 minutes to 120 hours, preferably 1 hour to 96 hours, more preferably 12 hours to 72 hours. Reaction temperature: usually 10 to 90°C, preferably 20 to 80°C, more preferably 30 to 50°C. pH of the reaction solution: usually 3-12, preferably 6-11, more preferably 7-11.

[0105] In addition, in the method for producing the compound of the present invention, the solvent used when the modified esterase of the present invention is allowed to act on the compound of formula I is not particularly limited as long as the modified esterase of the present invention can hydrolyze the compound of formula I to produce the compound of formula II. Examples of the relevant solvent include water, but are not limited thereto.

[0106] In a preferred embodiment of the method for producing the compound of the present invention, the substrate of the modified esterase of the present invention may be a compound represented by the following formula III.

[0107] [Chemistry 6]

[0108] In formula III, the structures of X2 and Y are not particularly limited and can be any structure. X2 and Y can be exemplified by hydrogen, halide (fluoro, chloro, bromo, iodo, astatinyl, etc.), alkyl (methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl, etc.) and aryl (phenyl, biphenyl and naphthyl, etc.), but are not limited to these. In addition, the carbon chains of these substituents can be straight chains or branched chains, and can have a cyclic structure or an unsaturated bond in the middle or at the end. In addition, these substituents can be further substituted by at least one of the substituents of (1) to (40) above. In addition, when there are two or more substituents, they can be the same or different. In addition, R is as described above.

[0109] In a preferred embodiment, X2 can be chloro, methyl or trifluoromethyl. In addition, Y can be chloro or methyl. R can be methyl or ethyl.

[0110] In a more preferred embodiment, X2 can be chloro, methyl or trifluoromethyl, Y can be chloro or methyl, and R can be methyl or ethyl.

[0111] In a further preferred embodiment, X2 is trifluoromethyl, Y is chloro and R is methyl (ie, (1R, 3R)-methyl cyhalothrin). Or X2 and Y are methyl and R can be ethyl (ie (1R, 3S)-chrysanthemic acid ethyl ester). Or X2 and Y are chloro groups and R can be methyl (ie (1R, 3R)-methyl permethrin).

[0112] The present invention will be further specifically described in the following examples, but the present invention is not limited to these examples. Example

[0113] A quintuple mutant of a wild-type esterase (sequence number 3) derived from Arthrobacter sphaeroides, an artificial esterase of sequence number 1 that is highly reactive to ethyl chrysanthemate, is slightly reactive to (1R,3R)-MC. Therefore, using this esterase as a reference esterase, an attempt was made to produce a modified esterase with improved reactivity to (1R,3R)-MC using protein engineering techniques. The detailed steps are shown below.

[0114] 1. Preparation of mutant library The mutant library was prepared according to the following method. (1) Introduction / transformation of mutations PCR primers for mutation introduction were designed to introduce NNK codons into the amino acids near the active center, and PCR was performed under the following conditions to introduce mutations.

[0115] <Primer> The primer No. 151 for preparing a mutant library and the primer No. 242 for preparing a mutant library are described below.

[0116] Primer at position 151 for making mutant library: F-primer sequence: NNKACCATCGGCGTCTTCATGGAGGAG (SEQ ID NO: 25) R-primer sequence: GGCGTGGTACCCGAAGGCGGTCCC (SEQ ID NO: 26) Primer 242 for making mutant library: F - primer sequence: NNKAGTTCAGCCGCCGGAGTCGCC (SEQ ID NO: 27) R - primer sequence: GCCGGCTGCGCGGACCTCGCGGAGG (SEQ ID NO: 28)

[0117] <Template plasmid> pET21b (import the gene sequence of the reference esterase) approximately 30 ng / μL

[0118] <PCR reaction composition> (total volume 20 μL) PrimeSTAR GXL Premix (Takara Bio): 10 μL Template (approximately 30 ng / μL): 1 μL F - primer: 0.2 μL R - primer: 0.2 μL Mix them and adjust the volume to 20 μL using ultrapure water (Milli Q water).

[0119] <PCR conditions> (1) 94°C, 30 seconds (2) <96°C, 10 seconds; 60°C, 15 seconds; 68°C, 6 minutes 30 seconds> × 20 cycles (3) 68°C, 5 minutes (4) Incubate at 4°C

[0120] Add 1.5 μL of DpnI to 15 μL of the PCR reaction solution and incubate (37°C, for more than 2 hours). Then, use 2 μL of the DpnI - treated solution and perform ligation using the following ligation reaction composition (16°C, O / N).

[0121] <Ligation reaction composition> (total volume 15 μL) DpnI - treated PCR product: 2 μL T4 polynucleotide kinase: 1 μL Ligation High (Toyobo): 5 μL Sterilized purified water: 7 μL

[0122] Use 2.5 μL of the ligation reaction solution and transform it (after treating at 42°C for 45 seconds, quickly cool on ice) into 25 μL of E. coli BL21(DE3). Spread approximately 100 μL of the transformation solution on an LB agar medium plate supplemented with ampicillin (final concentration 0.1 mg / mL) and culture it at 37°C, O / N (pre - culture).

[0123] (2) Obtaining enzyme extract Each mutant strain after pre-culture was inoculated into 1 mL of TB medium supplemented with ampicillin (final concentration 0.1 mg / mL). Cultured at 33°C for 48 hours (IPTG (final concentration 0.1 mM) was added 24 hours after the start of culture) and centrifuged (3,000g×15 minutes). After removing the supernatant and recovering the bacteria, the bacteria were lysed using a lysing agent (25°C, more than 2 hours). After centrifuging the lysate (3,000g×15 minutes), the supernatant was recovered as an enzyme extract.

[0124] (3) Preparation of combined mutants The obtained mutant was used as a template to carry out PCR in the same manner as in the above (1). The PCR product was recovered and an enzyme extract was prepared in the same manner as in the above (2).

[0125] (4) Preparation of multiple mutants Random mutagenesis was introduced by PCR using the DiversifyPCR Random Mutagenesis Kit (Takara Bio) using the L151F / L242M mutant as a template. The following primers were used.

[0126] Primers used for random mutagenesis: F-primer sequence: ATATGACCATGATTACGCC (SEQ ID NO: 29) R-primer sequence: TGGTGCTCGAGCTACTGAG (SEQ ID NO: 30)

[0127] After the ligation treatment, the mutant was transformed (treated at 42°C for 45 seconds and then chilled on ice) into 25 μL of E. coli BL21 (DE3) according to conventional methods. As an indicator of increased reactivity, trans-pNP chrysanthemic acid was used, and the free pNP amount was used as an indicator for screening. For the selected mutants, the enzyme extract was prepared using the same operation as above (2).

[0128] 2. Evaluation of Mutants 2-1. Evaluation of mutants The mutants were evaluated using the following method. Matrix: Methyl cyhalothricin ((1R, 3R) isoform: (1S, 3S) isoform = 50:50 mixture, purity above 90%) 5 μL of the matrix was dispensed into a reaction vessel, 95 μL of the enzyme extract (pH 7.5) was added, and the reaction was treated at 40°C for 24 hours until the reaction was stable. After treatment, 400 μL of acetonitrile was added. After sufficient stirring, centrifugation was performed, 5 μL of the organic layer was extracted, and diluted with 200 μL of 80% acetonitrile solution. The diluted solution was analyzed by ultra-high-speed high-resolution liquid chromatography (UPLC). The analysis conditions are shown below.

[0129] <Analysis conditions of ultra-high resolution liquid chromatography (UPLC)> Device: ACQUITY UPLC H-Class system PDA system (Waters) Chromatographic column: ACQUITY UPLC BEH C18 1.7 μm (Waters) Mobile phase: acetonitrile / water / TFA=60 / 40 / 0.1 Flow rate: 1.0mL / min Injection volume: 1μL Analysis time: 2 minutes / sample PDA detector: 210-400nm Resolution: 4.8nm

[0130] The change in reactivity to (1R,3R)-cyhalothricin methyl ester was evaluated based on the reactivity of the "standard esterase (composed of the amino acid sequence of SEQ ID NO: 1)". Specifically, the value of "the amount of trifluoroacetic acid produced in the reaction using the mutant" / "the amount of trifluoroacetic acid produced in the reaction using the standard esterase" was calculated from the area of ​​the UPLC region, and if the value exceeded 1, it was judged that the reactivity to (1R,3R)-cyhalothricin methyl ester increased.

[0131] The evaluation results are shown in Table 1. The following mutations were identified as substances that increase the reactivity to (1R,3R)-cyhalothricin methyl ester. In the reaction using the standard esterase, 10% of (1R,3R)-MA was converted to (1R,3R)-CA (conversion rate relative to the entire substrate was 5%).

[0132] [Table 1]

[0133] 2-2. Evaluation of double mutants 7 μL of the substrate was dispensed into a reaction vessel, 93 μL of the enzyme extract (pH 7.5) was added, and the reaction was treated at 40°C for 24 hours until the reaction was stable. After treatment, 400 μL of acetonitrile was added. After sufficient stirring, centrifugation was performed, 5 μL of the organic layer was extracted, and diluted with 200 μL of 80% acetonitrile solution. The diluted solution was analyzed and evaluated by ultra-high-resolution liquid chromatography (UPLC) in the same manner as in 2-1.

[0134] The evaluation results are shown in Table 2. The following mutations were identified as substances that increase the reactivity to (1R,3R)-cyhalothricin methyl ester.

[0135] [Table 2]

[0136] 2-3. Evaluation of multiple mutants 15 μL of the substrate was dispensed into a reaction vessel, 85 μL of the enzyme extract (pH 7.5 or pH 10) was added, and the reaction was treated at 40°C for 24 hours until the reaction was stable. After treatment, 400 μL of acetonitrile was added. After sufficient stirring, centrifugation was performed, 5 μL of the organic layer was extracted, and diluted with 200 μL of 80% acetonitrile solution. The diluted solution was analyzed and evaluated by ultra-high-resolution liquid chromatography (UPLC) in the same manner as in 2-1.

[0137] The evaluation results are shown in Table 3 (pH 7.5) and Table 4 (pH 10). The following mutations were identified as substances whose reactivity to (1R,3R)-cyhalothricin methyl ester was increased at pH 7.5 and pH 10.

[0138] [Table 3]

[0139] [Table 4]

[0140] 3. Evaluation of the Stereoselectivity of Mutants Three modified esterases (L151F / L242M / S329N, L151F / L242M / L200F, L151F / L242M / L200F / S329N) were prepared as follows. Each mutant strain was inoculated into 1 L of TB medium supplemented with ampicillin (final concentration 0.1 mg / mL). Cultured at 33°C for 48 hours (IPTG (final concentration 0.1 mM) was added 24 hours after the start of culture), and centrifuged (3,000g×15 minutes). After removing the supernatant and recovering the bacteria, the bacteria were lysed using a lytic agent (25°C, more than 2 hours). After centrifuging the lysate (3,000g×15 minutes), the supernatant was recovered. Concentrated using ultrafiltration, freeze-dried, and enzyme powder was obtained.

[0141] 3-1. Evaluation method of stereoselectivity The reactivity to cyhalothricin methyl ester ((1R, 3R): 50%, (1S, 3S): 50%) was evaluated using three kinds of mutant enzyme powder samples (L151F / L242M / S329N, L151F / L242M / L200F, L151F / L242M / L200F / S329N) and a standard esterase. 7.5 g of cyhalothricin methyl ester was added to a 100 mL conical flask, and 43.9 mL of 100 mM Gly-NaOH buffer at pH 10 was added, and stirred for a while. After that, each enzyme sample was added to each final concentration (standard esterase: 44U / mL, L151F / L242M / S329N: 21U / mL, L151F / L242M / L200F: 28U / mL, L151F / L242M / L200F / S329N: 6U / mL), and the pH was adjusted to around 9.8 using a 20% NaOH aqueous solution, and then reacted at 40°C for 48 hours. 400μL of acetonitrile and 100μL of the reaction solution were fully mixed using a 1.5mL test tube. After centrifuging the mixed sample at 10000G for 5min, a sample obtained by mixing 5μL of the supernatant with 200μL of 80% acetonitrile-water was analyzed by HPLC.

[0142] In addition, a solution of (1R,3R)-trifluorochloric acid with a known concentration was prepared, and the solution was analyzed by HPLC according to the procedure to prepare a calibration curve. The (1R,3R)-trifluorochloric acid produced by the enzyme reaction using the calibration curve was determined, and the conversion rate was calculated. The ratio of (1R,3S)-trifluorochloric acid in the product ((1R,3S)-trifluorochloric acid or (1R,3R)-trifluorochloric acid) was taken as the optical purity.

[0143] In addition, the definition and determination method of esterase activity are as follows:

[0144] In addition, when p-Nitrophenyl-butyrate (abbreviation: p-NPB) reacts with esterase as a substrate, p-nitrophenol is generated, and the absorbance at a wavelength of 416 nm increases. p-Nitrophenyl-butyrate (p-NPB, manufactured by SIGMA) is dissolved in Triton X-100 containing 1% of 0.1 M PIPES buffer (pH 7.0) to prepare a 2.5 mM p-NPB solution as the final concentration. Using an automatic analyzer TBA-120FR, 15 μL of the measurement sample (enzyme solution) is mixed with 300 μL of the p-NPB solution, and the absorbance change at 416 nm is measured. The amount of p-nitrophenol generated is calculated from the absorbance change at 416 nm, and the enzyme amount that generates 1 μmol of p-nitrophenol in 1 minute is defined as 1 unit.

[0145] In addition, the conditions of HPLC are as described below:

[0146] Evaluation of the reactivity to methyl cyhalothrin <HPLC Method> Apparatus: Waters H-class system Column: CHIRALCEL (registered trademark) OD-RH 4.6 mm Φ × 150 mm L Mobile phase: Acetonitrile / Water / TFA Gradient conditions: 30 / 70 / 0.1 (30 min) → 45 / 55 / 0.1 (5 min) → 45 / 55 / 0.1 (10 min) → 30 / 70 / 0.1 (3 min) → 30 / 70 / 0.1 (5 min) Flow rate: 1.0 mL / minute Injection volume: 5 μL Analysis time: 53 minutes / sample PDA detector: 210 nm

[0147] Evaluation of the reactivity to ethyl chrysanthemate <HPLC Method> Apparatus: Agilent 1290 HPLC Column: CHIRALCEL (registered trademark) OJ-RH 4.6 mm Φ × 150 mm L Mobile phase: Acetonitrile / Water / TFA Gradient conditions: 30 / 70 / 0.1 (30 min) → 45 / 55 / 0.1 (5 min) → 45 / 55 / 0.1 (10 min) → 30 / 70 / 0.1 (5 min) → 30 / 70 / 0.1 (5 min) Flow rate: 1.0 mL / minute Injection volume: 5 μL Analysis time: 55 minutes / sample PDA detector: 210 nm

[0148] In addition, the reactivity of methyl permethrate was evaluated in the same manner as that of ethyl chrysanthemate.

[0149] 3-2. Evaluation results of stereoselectivity When the amount of production of the reaction of (1R,3R)-trifluorocypermethrin acid from (1R,3R)-cypermethrin methyl ester when the standard esterase is used as the catalyst is set to 100%, the relative activities of the mutant enzymes are 235% for L151F / L242M / S329N, 230% for L151F / L242M / L200F, and 220% for L151F / L242M / L200F / S329N.

[0150] Moreover, the ratio (optical purity) of (1R,3R)-trifluorochloracetic acid in the product was 96% for the standard esterase, 96% for L151F / L242M / S329N, 95% for L151F / L242M / L200F, and 96% for L151F / L242M / L200F / S329N. Although all mutant enzymes showed higher conversion rates than the standard esterase, there was no effect on stereoselectivity.

[0151] 4. Evaluation of reactivity to similar matrices 4-1. Evaluation method Using two mutant enzyme powder samples (L151F / L242M / S329N, L151F / L242M / L200F) and a benchmark esterase (EYN7), the reactivity to chrysanthemic acid ethyl ester ((1R, 3R): 32.5%, (1S, 3S): 32.5%, (1R, 3S): 17.5%, (1S, 3R): 17.5%) and permethrin methyl ester ((1R, 3S): 32.5%, (1S, 3R): 32.5%, (1R, 3R): 17.5%, (1S, 3S): 17.5%) was evaluated. 7.5 g of substrate (chrysanthemic acid ethyl ester or permethrin methyl ester) was added to a 100 mL conical flask. 41.75 mL of 100 mM Gly-NaOH buffer at pH 10 was added and stirred for a while. After that, each enzyme sample was added to each final concentration (standard esterase: 70 U / mL, L151F / L242M / S329N: 33 U / mL, L151F / L242M / L200F: 44 U / mL), and the pH was adjusted to around 9.8 using a 20% NaOH aqueous solution, followed by reaction at 40°C for 48 hours.

[0152] 400 μL of acetonitrile and 100 μL of the reaction solution were thoroughly mixed in a 1.5 mL test tube, the mixed sample was centrifuged at 10000 G for 5 min, and then 25 μL of the supernatant and 1 mL of 80% acetonitrile-water were mixed and analyzed by HPLC.

[0153] In addition, a solution of (1R,3S)-chrysanthemic acid with a known concentration was prepared and analyzed by HPLC according to the same procedure to prepare a calibration curve. The (1R,3S)-chrysanthemic acid generated by the enzyme reaction was determined using the calibration curve to calculate the conversion rate.

[0154] (1R,3R)-chrysanthemic acid was evaluated by comparing the peak area value with (1R,3S)-chrysanthemic acid. The ratio of (1R,3S)-chrysanthemic acid in the product ((1R,3S)-chrysanthemic acid or (1R,3R)-chrysanthemic acid) was used as the optical purity. For methyl permethrate, the reactivity was evaluated by the peak area value of (1R,3R)-dichloropermethric acid ((1R,3R)-permethric acid) and (1R,3S)-dichloropermethric acid. The ratio of (1R,3S)-dichloropermethric acid in the product was used as the optical purity. Evaluated by (1R,3R)-dichloropermethric acid and (1R,3S)-dichloropermethric acid. The ratio of (1R,3R)-dichloropermethric acid in the product ((1R,3R)-dichloropermethric acid or (1R,3S)-dichloropermethric acid) was used as the optical purity.

[0155] 4-2. Evaluation results Conversion rate of (1R,3S)-chrysanthemic acid and specificity of (1R,3S)-chrysanthemic acid ethyl ester When the amount of production of (1R,3S)-chrysanthemic acid from (1R,3S)-chrysanthemic acid ethyl ester when the standard esterase is used as the catalyst is set to 100%, the relative activities of the mutant enzymes are 126% for L151F / L242M / S329N and 128% for L151F / L242M / L200F.

[0156] The optical purity was 94% for the benchmark esterase, 100% for L151F / L242M / S329N, and 94% for L151F / L242M / L200F. Although all mutant enzymes showed higher conversion rates than the benchmark esterase, there was no effect on stereoselectivity.

[0157] Conversion rate to (1R,3R)-dichloropermethrin and specificity to (1R,3R)-methyl permethrin When the amount of production of (1R,3R)-permethrin acid from (1R,3R)-methyl permethrin when the standard esterase is used as the catalyst is set to 100%, the relative activities of the mutant enzymes are 159% for L151F / L242M / S329N and 157% for L151F / L242M / L200F.

[0158] The optical purity was 79% for the benchmark esterase, 88% for L151F / L242M / S329N, and 79% for L151F / L242M / L200F. Although all mutant enzymes showed higher conversion rates than the benchmark esterase, there was no effect on stereoselectivity. Industrial Applicability

[0159] By using the modified esterase of the present invention, (1R,3R)-CA, which is an important intermediate of pesticides, can be efficiently produced. Therefore, the present invention is extremely useful in the field of pesticide production, for example.

[0160] This application is based on Japanese Patent Application No. 2022-063122 (filing date: April 5, 2022), the entire contents of which are incorporated herein by reference.

Claims

1. A modified esterase, which is any one of the following modified esterases (i) to (iii): (i) a modified esterase comprising an amino acid sequence in which at least one amino acid at a position selected from the group consisting of the following (1) to (24) in the amino acid sequence of SEQ ID NO: 1 or 3 is substituted with another amino acid; (1)V64 (2)S65 (3)A102 (4)A109 (5)L151 (6)I153 (7)Y173 (8)Y197 (9)L200 (10)I211 (11)F217 (12)S220 (13)D222 (14)D227 (15)L229 (16)L242 (17)A245 (18)V257 (19)L298 (20)T301 (21)V326 (22)S329 (23)A350 (24)T371 (ii) A modified esterase, wherein one or more amino acids are further replaced, added, inserted or deleted in the modified esterase of (i), and the reactivity thereof to (1R,3R)-methyl-3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylate is further improved compared to the reactivity of the esterase consisting of the amino acid sequence of SEQ ID NO: 1 or 3; however, the amino acid site replaced in (i) is excluded in the replacement, and the amino acid site replaced in (i) is excluded in the deletion; (iii) A modified esterase, wherein in the modified esterase of (i), an amino acid other than the amino acid substituted in (i) is further substituted with another amino acid, the modified esterase having an identity of 70% or more with the modified esterase of (i), and having a reactivity to (1R,3R)-methyl-3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylate that is further improved compared to the reactivity of the esterase consisting of the amino acid sequence of SEQ ID NO: 1 or 3.

2. The modified esterase according to claim 1, wherein in (i), the amino acid substitution is at least one selected from the group consisting of: (1) V64M (2)S65A (3)A102S (4)A109T (5) L151F, L151M or L151W (6)I153V (7)Y173F (8)Y197F (9) L200F (10)I211V or I211M (11)F217K (12)S220W (13)D222G (14) D227C or D227E (15)L229G (16) L242C, L242I, L242M or L242W (17)A245T (18)V257I (19)L298H (20)T301A (21)V326I (22) S329D, S329G or S329N (23) A350D (24)T371A.

3. A nucleic acid encoding the modified esterase according to claim 1 or 2. An expression cassette or a recombinant vector comprising the nucleic acid according to claim 3.

5. A transformant obtained by transformation using the expression cassette or recombinant vector according to claim 4. 6 . A method for producing a modified esterase, comprising the step of culturing the transformant according to claim 5 .

7. An enzyme agent comprising the modified esterase according to claim 1 or 2. 8 . The enzyme agent according to claim 7 , which is used for producing (1R,3R)-3-((1Z)-2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylic acid.

9. A method for producing (1R,3R)-3-((1Z)-2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylic acid, comprising the step of allowing the modified esterase according to claim 1 or 2 to act on (1R,3R)-methyl-3-(2-chloro-3,3,3-trifluoro-1-propene-1-yl)-2,2-dimethylcyclopropane-1-carboxylate.

Citation Information

Patent Citations

  • Modified chrysanthemic acid esterase

    WO2020116331A1